Venlafaxine:a novel antidepressant compound

Bibliography

• YARDLEY JP, MORRIS HUSBANDS GE, STACK G et al: 2-Phenyl-2-0-hydroxycycloalkyDethylamine deriva-tives: synthesis and antideprasant activity. J. Med. Chem. (1990) 33:2899–2905.
   PubMed Web of Science ®Google Scholar
• MUTH EA, HASKINS JT, MOYER JA et al: Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol (1986) 35:4493–4497.
   PubMed Web of Science ®Google Scholar
• BOLDEN-WATSON C, RICHELSON E: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. (1993) 52:1023–1029.
   PubMed Web of Science ®Google Scholar
• DE BOER TH, MAURA G, RAITERI M et al.: Neurochemical and autonomic pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology (1988) 27:399–408.
   PubMed Web of Science ®Google Scholar
• RICHELSON E: Biological basis of depression and thera-peutic relevance. J. Clin. Psychiatry (1991) 52\(Suppl. 6):4–10.
   Google Scholar
• MUTH EA, CILMI KM: WY-45,030, a new antidepressant, and zimelidine decrease 5-HIAA levels in whole rat brain. Soc. Neurosci. Abstr. (1985) 11:185.
   Google Scholar
• HASKINS JT, MOYER JA, MUTH EA, SGG EB: DMI, WY-45,030, WY-45,881 and ciramadol inhibit locus co-eruleus neuronal activity. Eur. j Pharmacol. (1985) 115:139–146.
   PubMed Web of Science ®Google Scholar
• BELQUE JC, DE MONTIGNY C, BLIER P, DEBONNEL G:Blockade of 5-HT and NE reuptake by venlafaxine: in vivo electrophysiological studies in the rat. Soc. Neuro-sci. Abstr. (1996) 22:180.
   Google Scholar
• MUTH EA, MOYER JA, HASKINS JT et al.: Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antide-pressant venlafaxine. Drug Dev. Res. (1991) 23:191–199.
   Web of Science ®Google Scholar
• RICHELSON E: The pharmacology of antidepressants at the synapse: focus on new compounds. J. Clin. Psychiatry (1994) 55 (Suppl. 9):34–41.
   Google Scholar
• CUSACK B, NELSON A, RICHELSON E: Binding of antide-pressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (1994) 114:559–565.
   PubMed Web of Science ®Google Scholar
• FRAZER A, CONWAY P: Pharmacologic mechanisms ofaction of antidepressants. Psychiat. Clin. North Am. (1984) 7:575–586.
   PubMed Web of Science ®Google Scholar
• DE MONTIGNY C, CHAPUT Y, BLIER P: Modification of ser otonergic neuron properties by long-te I'm treatment with serotonin ruptake blockers. j Clin. Psychiatry (1990) 51 (Suppl.
   Google Scholar
• SULSER F: Functional aspects of the noradrenaline re-ceptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipi-tate or alleviate depression: molecular approaches to an understanding of affective disorders. Pharmakopsy-chiafr. Neuropsychopharmacol. (1978)43–52.
   Google Scholar
• BLIER P, DE MONTIGNY C: Current advances and trendsin the treatment of depression. Trends Pharmacol Sci. (1994) 15:220–226.
   PubMed Web of Science ®Google Scholar
• FRAZER A, PANDEY G, MENDELS J, NEELEY S, HESS ME:The effect of triiodothyronine on rll, -cyclic AMP production in slices of rat cerebral cortex. Neuropharma-cology(1974) 3:1131–1140.
   Google Scholar
• VETULANI J, SULSER F: Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature (1975) 257:495–496.
   PubMed Web of Science ®Google Scholar
• BANERJEE SP, KUNG IS, CHANDA SK: Development of P-adrenergic receptor subansitivity by antidepres-sants. Nature (1977) 268:455–456.
   PubMed Web of Science ®Google Scholar
• ORDWAY GA, GAMBARANA C, TEJANI-BUTT SM et al: Preferential reduction of binding of [1251] -iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J. Pharmacol Exp. Ther. (1991) 257(2)681–690.
   Google Scholar
• MOYER JA, GREENBERG LH, FRAZER A et al.: Opposite effects of acute and repeated administration of des-methylimipramine on adrenergic responsiveness in rat pineal gland. Life Sci. (1979) 24:2237–2244.
   PubMed Web of Science ®Google Scholar
• MOYER JA, MUTH EA, HASKINS JT, LAPPE RW, SIGG EB: In vivo antidepressant profile of the novel bicyclic compounds WY-45,030 and WY-45,881. Soc. Neurosci. Abstr. (1984) 10:261.
   Google Scholar
• NALEPA I, HAL MANIER D, GILLESPIE DD et al: Dual signaling by venlafaxine: I. The beta adrenoceptor desensitization hypothesis revisited. Submitted (personal c ommunication) .
   Google Scholar
• OZAWA H, RASENICK MM: Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Mol. Pharmacol. (1989) 36:803–808.
   PubMed Web of Science ®Google Scholar
• NESTLER EJ, TERWILLIGER RZ, DUMAN RS: Chronic anti-depressant administration alters the subcellular distri-bution of cyclic AMP-dependent protein kinase in rat frontal cortex. J. Neurochem. (1989) 53:1644–1647.
   PubMed Web of Science ®Google Scholar
• PEREZ J, TINELLI D, BIANCHI E, BRUNELLO N, RACAGNI G: cAMP binding proteins in the rat ce rebra 1 cort ex after administration of selective 511T and NE reuptake block-ers with antidepressant activity. Neuropsychopharmacol-ogy (1991) 4:57–64.
   PubMed Web of Science ®Google Scholar
• POPOLI M, VOCATURO C, PEREZ J, SMERALDI E, RACAGNI G: Presynaptic Ca2±/calmodulin-dependent protein ki-nase II: autophosphorylation and activity increase in the hippocampus after long-termblo ckade of serotonin reuptake. Mol Pharmacol. (1995) 48:623–629.
   PubMed Web of Science ®Google Scholar
• DETKE MJ, RICKELS M, LUCKI I: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psy-chopharmacology (1995) 121:66–72.
   PubMed Web of Science ®Google Scholar
• RENERIC JPH, LUCKI I: Serotonergic and noradrenergic mechanisms involved in the effects of antidepressants in the rat forced swimming test (FST). Soc. Neurosci. Abstr. (1996) 22:181.
   Google Scholar
• MITCHELL PJ, FLETCHER A, REDFERN PH: Is antidepres-sant efficacy revealed by drug-induced changes in rat behaviour exhibited during social inter acti on?Neurosci. Biobehav. Rev. (1991) 15:539–544.
   PubMed Web of Science ®Google Scholar
• MITCHELL PJ, FLETCHER A: Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology (1993) 32:1001–1009.
   PubMed Web of Science ®Google Scholar
• FABRE LF, PUTMAN HP: An ascending single-dose toler-ance study of WY-45,030, a bicyclic antidepressant, in healthy men. Curr. Ther. Res. (1987) 42:901–909.
   Web of Science ®Google Scholar
• KLAMERUS KJ, MALONEY K, RUDOLPH RL et al: Introduc-tion of a composite parameter to the pharmacokine tics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol (1992) 32:716–724.
   PubMed Web of Science ®Google Scholar
• OTTON SV, BALL SE, CHEUNG SW et al.: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol (1996) 41:149–156.
   PubMed Web of Science ®Google Scholar
• RIESENMAN C: Antidepressant drug interactions andthe cytochrome P450 system: a critical appraisal. Pharma-cotherapy (1995) 15:84S–99S.
   Google Scholar
• HOWELL SR, HUSBANDS GEM, SCATINA JA, SISEN WINE SF: Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica (1993) 23:349–359.
   PubMed Web of Science ®Google Scholar
• WANG CP, HOWELL SR, SCATINA J, SISENWINE SF: Thedisposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirali07(1992) 4:84–90.
   PubMed Web of Science ®Google Scholar
• TROY SM, PARKER VD, FRUNCILLO RJ, CHIANG ST: The pharmacokinetics of venlafa xine when give n in a twice - daily regimen. J. Clin. Pharmacol (1995) 35:404–409.
   PubMed Web of Science ®Google Scholar
• TROY SM, SCHULTZ RW, PARKER VD, CHIANG ST, BLUM RA: The effect of renal disease on the disposition of venlafaxine. Clin. Pharmacol. Ther. (1994) 56:14–21.
   PubMed Web of Science ®Google Scholar
• MORTON WA, SONNE SC, VERGA MA: Venlafaxine: a structurally unique and novel antickpressant. Ann. Pharmacother. (1995) 29:387–395.
   PubMed Web of Science ®Google Scholar
• ERESHEFSKY L: Drug-drug interactions involving anti-depressants: focus on venlafaxine. j Clin. Psychophar-macol. (1996) 16\(Suppl. 2):37S–53S.
   Google Scholar
• FEIGHNER JP: The role of venlafaxine in rational anti-depressant therapy. J. Clin. Psychiat (1994) 55 (Suppl. A):62–68.
   Google Scholar
• BALL S, AHERN D, KAO J, SCATINA J: Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation: comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP2A4 and CYP2C9. Clin. Pharmacol. Ther. (1996) 59:170.
   Google Scholar
• WIKLANDER B, DANJOU P, ROLAN P, TAMIN SK TOON S: Evaluation of the potential pharmacokinetic interac-tion of venlafaxine and carbamazepine. Eur. NeuropF-chopharmacol (1995) 5:310–311.
   Google Scholar
• TROY SM, LUCKI I, PEIRGIES AA et al.: Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J. Clin. Pharmacol. (1995) 35:410–419.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB, DE VANE CL, POLLOCK BG: Newer anti-depressants and the cytochrome P450 system. Am. J. Psychiatry (1996) 153:311–320.
   PubMed Web of Science ®Google Scholar
• PARKER V, TROY S, RUDOLPH R, CONRAD K, CHIANG S.The potential pharmacokinetic interaction between venlafaxine and lithium carbonate. J. Gin. Pharmacol (1991) 31:866.
   Google Scholar
• KLYSNER R, LARSEN JK, SORENSEN P, HYLLESTED M, PEDERSEN BD: Toxic interaction of venlafaxine and is ocarboxazide [letter]. Lancet (1995) 346:1298–1299.
   PubMed Web of Science ®Google Scholar
• HEISLER MA, GUIDY JR, ARNECKE B: Serotonin syndromeinduced by administration of venlafaxine and phe nelz-ine [letter]. Ann. Pharmacother. (1996) 30:84.
   PubMed Web of Science ®Google Scholar
• PHILLIPS SD, RINGO P: Phenelzine and venlafaxine in-teraction [letter]. Am. J. Psychiat (1995) 152:1400–1401.
   PubMed Web of Science ®Google Scholar
• RUDOLPH RL, DERIVAN AT: The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J. Clin. Psychopharmacol (1996) 16\(Suppl. 2):54S–615.
   Google Scholar
• DANJOU P, HACKETT D: Safety and tolerance profile of venlafaxine. Int Clin. Psychopharmacol (1995) 10\(Suppl. 2):15–20.
   Google Scholar
• SALETU B, GRUNBERGER J, ANDERER P, SEMLITSCH HV, MAGNI G: Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry, and psycho-physiology. Br. J. Clin. Pharmacol (1992) 33:589–601.
   PubMed Web of Science ®Google Scholar
• SEMILITSCH HV, ANDERER P, SALETU B, BINDER GA, DECKER KA: Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate, and mood in young health subjects. Int Clin. Psychopharmacol. (1993) 8:155–166.
   PubMed Web of Science ®Google Scholar
• TROY S, PIERGIES A, LUCKI I: Venlafaxine pharmacoki-netics and pharmacodynamics [abstract]. Clin. Neuro-pharmacol. (1992) 15 (Sup pl. 1):324B.
   Google Scholar
• LUTHRINGER R: A double-blind, placebo-controlled evaluation of the effects of venlafaxine on sleep in in-patients with major depression. NCDEU Meeting. Boca Raton, FL (May 1996).
   Google Scholar
• FARAH A, LAUER TE: Possible venlafaxine withdrawal [letter]. Am. J. Psychiatry (1996) 153:576.
   PubMed Web of Science ®Google Scholar
• MENDELS J, JOHNSTON R, MATTES J, RIESENBERG R: Efficacy and safety of BID doses of venlafaxine in a dose response study. Psychopharmacol Bull. (1993) 29:169–174.
   PubMed Web of Science ®Google Scholar
• DIERICK M, RAVIZZA L, REALINI R, MARTIN A: A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression. Prog. Neuropsychophar-macol Biou. Psychiat. (1996) 20:57–71.
   PubMed Web of Science ®Google Scholar
• KHAN A, FABRE LF, RUDOLPH R: Venlafaxine in de-pressed out-patients. Psychopharmacol Bull (1991) 27:141–144.
   PubMed Web of Science ®Google Scholar
• SCHVVEIZER E, WEISE C, CLARY C, FOX I, RICKELS K:Placebo-controlled trial of venlafaxine inthe treatment of major depression. J Clin. Psychopharmacol (1991) 11:233–236.
   PubMed Web of Science ®Google Scholar
• SHRIVASTAVA R, PATRICK R, SCHERER N: A dose-re-sponse study of venlafaxine. Neuropsychopharmacology (1994) 10:221S.
   Google Scholar
• BENKERT O, HACKETT D, REALINI R, WHITE C, DE WILDE J: A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in in-patients with major depression. Neuropsychopharmacol-ogy (1994) 10\(Suppl. 1):165S.
   Google Scholar
• SHRIVASTAVA RK, COHN C, CROWDER J et al: Long-term safety and clinical acceptability of venlafaxine and imipramine in out-patients with major depression. J. Clin. Psychopharmacol (1994) 14:322–329.
   PubMed Web of Science ®Google Scholar
• SCHVVEIZER E, FEIGHNER J, MANDOS LA, RICKELS K: A comparison of venlafaxine and imipramine in the acute treatment of major depression in out-patients. J. Clin. Psychiatry (1994) 55:104–108.
   PubMed Web of Science ®Google Scholar
• SAMUELIAN JC, TATOSSIAN A, HACKETT D: A random-ized, double-blind, parallel group comparison of ven-lafaxine and clomipramine in out-patients with major depression. Clin. Neuropharmacol (1992) 15\(Suppl. 1):324B.
   Google Scholar
• CUNNINGHAM LA, BORISON RL, CARMAN JS et al: A comparison of venlafaxine, trazodone, and placebo in major depression. J. Clin. Psychopharmacol. (1994) 14:99–106.
   PubMed Web of Science ®Google Scholar
• FRAZER A: Antidepressant drugs. Depression (1994) 2:1–19.
   Google Scholar
• GUELFI JD, WHITE C, HACKETT D, GUICHOUX JY, MAGNI G: Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J. Gin. Psychia-try (1995) 56:450–458.
   Google Scholar
• DERIVAN A, ENTSAUH AR, KIKTA D: Venlafaxine: meas-uring the onset of antidepressant action. Psychopharma-col. Bull. (1995) 31:439–447.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER E, RICKELS K, AMSTERDAM JD et al: What constitutes an adequate antidepressant trial for fluoxet-ine?j Clin. Psychiafty (1990) 51:8–11.
   Google Scholar
• BEASLEY CM, Jr., HOLMAN SL, POTVIN JH: Fluoxetine compared with imipramine in the treatment of in-pa-tient depression. A multicenter trial. Ann. Clin. Psychia-try (1993) 5:199–207.
   PubMedGoogle Scholar
• TIGNOL J: A double-blind, randomized, fluoxetine-con-trolled, multicenter study of paroxetine in the treat-ment of depression. J. Clin. Psychopharmacol (1993) 13\(Suppl. 2):185–225.
   Google Scholar
• ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Com-parative efficacy of selective serotoninreuptake inhibi-tors and tricyclics in the treatment of melancholia. Am. Psychiatry (1994) 151:1735–1739.
   PubMed Web of Science ®Google Scholar
• CLERC GE, RUIMY P, VERDEAU-PAILLES J: A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Psychopharmacol (1994) 9:139–143.
   PubMed Web of Science ®Google Scholar
• NIERENBERG AA, FEIGHNER JP, RUDOLF R, COLE JO, SULLIVAN J: Venlafaxine for treatment-resistant unipo-lar depression. J. Clin. Psychopharmacol (1994) 14:419–423.
   PubMed Web of Science ®Google Scholar
• MAGNI G, HACKETT D: An open-label evaluation of the long-term safety and clinical acceptability of venlafax-ine in depressed patients. Clin. Neuropharmacol (1992) 15\(Suppl. 1):323B.
   Google Scholar
• TILLER J, JOHNSON G, O'SULLIVAN B: Venlafaxine: a long-term study. Gin. Neuropharmacol. (1992) 15\(Suppl. 1):342B.
   Google Scholar
• ENTSUAH R, RUDOLPH R, DERIVAN A, RICKELS K. A low relapse rate confirms the long-term efficacy of venla-faxine in the treatment of major depression. Abstracts of Panels and Posters, Poster Session II, ACNP Meeting. Honolulu, Hawaii (1993):192.
   Google Scholar
• Psychiatric Disorders in America: the Epidemiologic Catch-ment Area Study Robins LN, Regier DA (Eds.), The Free Press, New York (1991).
   Google Scholar
• GERACIOTI TD, Jr.: Venlafaxine treatment of panic dis-order: a case series. J Clin. Psychiatry (1995) 56:408–410.
   PubMed Web of Science ®Google Scholar
• POLLACK M: Double-blind, placebo-controlled trial of venlafaxine for panic disorder. NCDEU Meeting. Boca Raton, FL (May 1996).
   Google Scholar
• ANANTH J, BURGOYNE K, SMITH M, SWARTZ R: Ve nla fax-ine for the treatment of obsessive-compulsive disorder [letter]. Am. J. Psychiatry (1995) 152:1832.
   PubMed Web of Science ®Google Scholar
• GROSSMAN R, HOLLANDER E: Treatment of obsessive-compulsive disorder with venlafaxine [letter]. Am. J. Psychiatry (1996) 153:576–577.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ:Venlafaxine in adults with attention-deficit /hyp eractiv-ity disorder: an open clinical trial. J. Clin. Psychiatry (1996) 57:184–189.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TJ: Venlafaxine foradult ADHD [letter]. Am. J. Psychiatry (1995) 152:1099–1100.
   PubMedGoogle Scholar
• HORNIG-ROHAN M, AMSTERDAM JA: Venlafaxine for thetreatment of adult attention deficit disorder co-morbid with depression. NCDEU Meeting. May (1995).
   Google Scholar
• DWIGHT M: Venlafaxine treatment of fibromyalgia.NCDEU Meeting. Boca Raton, FL (May 1996).
   Google Scholar
• DIAMOND S: Efficacy and safety profile of venlafaxinein chronic headache. Headache Quarterly (1995) 6:212–214.
   Web of Science ®Google Scholar
• MARKVITZ PJ, WAGNER SC: Venlafaxine in the treatmentof borderline personality disorder. Psychopharmacol Bull. (1995) 31:773–777.
   PubMed Web of Science ®Google Scholar